These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

299 related items for PubMed ID: 22727797

  • 1. 1:1 atrial flutter after vernakalant administration for atrial fibrillation cardioversion.
    de Riva-Silva M, Montero-Cabezas JM, Salgado-Aranda R, López-Gil M, Fontenla-Cerezuela A, Arribas-Ynsaurriaga F.
    Rev Esp Cardiol (Engl Ed); 2012 Nov; 65(11):1062-4. PubMed ID: 22727797
    [No Abstract] [Full Text] [Related]

  • 2. Atrial flutter with 1 : 1 atrioventricular conduction after administration of vernakalant for atrial fibrillation.
    Franzini C, Müller-Burri SA, Shah DC.
    Europace; 2014 Jan; 16(1):3. PubMed ID: 24344323
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. [Vernakalant--a new drug for pharmacological conversion of atrial fibrillation].
    Hinneburg I.
    Med Monatsschr Pharm; 2011 May; 34(5):154-8. PubMed ID: 21644373
    [Abstract] [Full Text] [Related]

  • 5. [New concepts in the therapy of atrial fibrillation].
    Shin DI, Eckardt L.
    Dtsch Med Wochenschr; 2011 Aug; 136(31-32):1587-90. PubMed ID: 21809248
    [No Abstract] [Full Text] [Related]

  • 6. A randomized, placebo-controlled study of vernakalant (oral) for the prevention of atrial fibrillation recurrence after cardioversion.
    Torp-Pedersen C, Raev DH, Dickinson G, Butterfield NN, Mangal B, Beatch GN.
    Circ Arrhythm Electrophysiol; 2011 Oct; 4(5):637-43. PubMed ID: 21841207
    [Abstract] [Full Text] [Related]

  • 7. A new antiarrhythmic drug in the treatment of recent-onset atrial fibrillation: vernakalant.
    Vizzardi E, Salghetti F, Bonadei I, Gelsomino S, Lorusso R, D'Aloia A, Curnis A.
    Cardiovasc Ther; 2013 Oct; 31(5):e55-62. PubMed ID: 23398692
    [Abstract] [Full Text] [Related]

  • 8. Usefulness of vernakalant hydrochloride injection for rapid conversion of atrial fibrillation.
    Pratt CM, Roy D, Torp-Pedersen C, Wyse DG, Toft E, Juul-Moller S, Retyk E, Drenning DH, Atrial Arrhythmia Conversion Trial (ACT-III) Investigators.
    Am J Cardiol; 2010 Nov 01; 106(9):1277-83. PubMed ID: 21029824
    [Abstract] [Full Text] [Related]

  • 9. Vernakalant: A novel agent for the termination of atrial fibrillation.
    Finnin M.
    Am J Health Syst Pharm; 2010 Jul 15; 67(14):1157-64. PubMed ID: 20592320
    [Abstract] [Full Text] [Related]

  • 10. Pharmacological cardioversion of atrial fibrillation with vernakalant: evidence in support of the ESC Guidelines.
    Savelieva I, Graydon R, Camm AJ.
    Europace; 2014 Feb 15; 16(2):162-73. PubMed ID: 24108230
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Intravenous vernakalant for the rapid conversion of recent onset atrial fibrillation: systematic review and meta-analysis.
    Guerra F, Matassini MV, Scappini L, Urbinati A, Capucci A.
    Expert Rev Cardiovasc Ther; 2014 Sep 15; 12(9):1067-75. PubMed ID: 25096598
    [Abstract] [Full Text] [Related]

  • 13. Vernakalant, a mixed sodium and potassium ion channel antagonist that blocks K(v)1.5 channels, for the potential treatment of atrial fibrillation.
    Billman GE.
    Curr Opin Investig Drugs; 2010 Sep 15; 11(9):1048-58. PubMed ID: 20730700
    [Abstract] [Full Text] [Related]

  • 14. Is vernakalant better or not, compared with other treatments for conversion of acute atrial fibrillation?
    Conde D.
    Int J Cardiol; 2013 Oct 30; 169(2):95-6. PubMed ID: 24071384
    [Abstract] [Full Text] [Related]

  • 15. Novel agents for the acute conversion of atrial fibrillation: focus on vernakalant.
    Cialdella P, Pedicino D, Santangeli P.
    Recent Pat Cardiovasc Drug Discov; 2011 Jan 30; 6(1):1-8. PubMed ID: 21235460
    [Abstract] [Full Text] [Related]

  • 16. Vernakalant versus electrical cardioversion in recent-onset atrial fibrillation.
    Conde D, Lalor N, Rodriguez L, Elissamburu P, Marcelo T.
    Int J Cardiol; 2013 Oct 09; 168(4):4431-2. PubMed ID: 23890913
    [No Abstract] [Full Text] [Related]

  • 17. Effectiveness and safety of vernakalant vs flecainide for cardioversion of atrial fibrillation in the emergency department: the VERITA study.
    Dominijanni G, Caballero-Bermejo AF, Martín Jiménez ML, Calpe Delgado P, Rodríguez-Miranda B, Ruiz-Antorán B.
    Emergencias; 2024 Jun 09; 36(3):239-240. PubMed ID: 38819000
    [No Abstract] [Full Text] [Related]

  • 18. Vernakalant: additional evidence for safety and efficacy for new onset atrial fibrillation.
    Lindsay BD.
    J Am Coll Cardiol; 2011 Jan 18; 57(3):322-3. PubMed ID: 21232670
    [No Abstract] [Full Text] [Related]

  • 19. [Success of pharmacologic cardioversion and electric cardioversion in patients with atrial fibrillation or flutter in a 5-year retrospective study].
    Bugán V, Renker B, Brunclík P, Baraniková D, Augustín E.
    Vnitr Lek; 1994 Apr 18; 40(4):219-22. PubMed ID: 8184582
    [Abstract] [Full Text] [Related]

  • 20. Predictors of successful cardioversion with vernakalant in patients with recent-onset atrial fibrillation.
    Mochalina N, Juhlin T, Öhlin B, Carlson J, Holmqvist F, Platonov PG.
    Ann Noninvasive Electrocardiol; 2015 Mar 18; 20(2):140-7. PubMed ID: 25040826
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 15.